Results 231 to 240 of about 96,415 (362)

The global prevalence of headache disorders of public-health importance: a meta-analysis of population-based individual participant data from 41,614 adults from 17 countries. [PDF]

J Headache Pain
Husøy AK, Yu S, Liu R, Herekar AA, Ahmed B, Herekar AD, Tegueu CK, Tamdja AD, Magnerou AM, Kissani N, Adarmouch L, Adoukonou T, Agbetou M, Kossi O, Zebenigus M, Teckle-Haimanot R, Worku DK, Rao GN, Kulkarni GB, Gururaj G, Jumah MA, Khathaami AMA, Quispe G, Palomino-Diaz C, Linde M, Risal A, Anand K, Chowdhury D, Duggal A, Luvsannorov O, Enkhtuya S, Baldorj D, Ayzenberg I, Katsarava Z, Andrée C, Birbeck GL, De la Torre ER, Rastenytė D, Thomas H, Stovner LJ, Steiner TJ.   +40 more
europepmc   +1 more source

Characterizing sleep, headache‐related disability, and psychological functioning among adolescents with continuous headache: A pilot study from a tertiary clinical setting

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Youth with continuous headache are understudied, are presumed to be more psychosocially complex and impaired than youth with remitting headache presentations, and are at risk for poor clinical outcomes. Given links between sleep and pain, characterizing sleep among youth with continuous headache may inform intervention ...
Ellie C. Adam, Robert C. Gibler, Dean W. Beebe, Scott W. Powers, Andrew D. Hershey, Marielle Kabbouche, Joanne Kacperski, Brooke L. Reidy   +7 more
wiley   +1 more source

Association between migraine and depression, anxiety, and stress in the Aseer region: a cross-sectional study. [PDF]

Front Neurol
Abumilha AKY, Abukaftah ASA, Al-Mudhi MM, Al Fareh NA, Muflih Abudasser A.   +4 more
europepmc   +1 more source

Differential outcomes in familial and sporadic SCN8A self‐limited infantile epilepsies: Insights from a large international registry

Epilepsia, EarlyView.
Francesca Furia, Sopio Gverdtsiteli, Wibke Janzarik, Christian Korff, Gaetan Lesca, Maria Margherita Mancardi, Martino Montomoli, Marina Nikanorova, Romina Romaniello, Guido Rubboli, Steffen Syrbe, Federico Vigevano, Rikke S. Møller, Elena Gardella   +13 more
wiley   +1 more source

Effectiveness and tolerability of liraglutide as add‐on treatment in patients with obesity and high‐frequency or chronic migraine: A prospective pilot study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess whether glucagon‐like‐peptide‐1 receptor (GLP‐1R) agonists could serve as a novel prophylactic treatment for migraine in patients with obesity. Background Increased intracranial pressure (ICP) is speculated to play a role in migraine mechanisms, as chronic migraine and idiopathic intracranial hypertension without ...
Simone Braca, Cinzia Valeria Russo, Antonio Stornaiuolo, Gennaro Cretella, Angelo Miele, Caterina Giannini, Roberto De Simone   +6 more
wiley   +1 more source

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This randomized trial was designed to test the effectiveness and safety of rimegepant for the acute treatment of migraine among adults in Japan. Results indicated that rimegepant was more effective than placebo, and the 75 mg dose was observed to be more effective than the 25 mg dose.
Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

Differential resting-state MEG microstate patterns in migraineurs: a cross-sectional study. [PDF]

J Headache Pain
He P, Li C, Sun W, Chen N, Ma M, Fang J, Li S, Lang H, Xing H, He L.   +9 more
europepmc   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Evaluation of Personality Profiles in Cluster Headache Patients: A Comparative Analysis with Migraine Patients Using the Minnesota Multiphasic Personality Inventory-3. [PDF]

J Clin Med
Zmork-Martínez GR, Higuera-Ruiz-de-la-Hermosa A, Portocarrero-Sánchez L, Díaz-de-Terán J.   +3 more
europepmc   +1 more source

Use of antimigraine medication before pregnancy and in the first trimester: A cross‐sectional study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Migraine is common among women, particularly during their reproductive years. There is limited research on the use of antimigraine medication before and during pregnancy. This study was undertaken to describe the use of antimigraine medication 3 months before pregnancy and in the first trimester among women with migraine ...
Stine Wieland, Marie S. Emborg, Mie G. de Wolff, Peter Damm, Line Buchgreitz, Mona A. Chalmer, Hanne K. Hegaard, Ane L. Rom   +7 more
wiley   +1 more source